Flucinar, 0.025% ointment 15 g

Flucinar is a synthetic GKS for external use. It has anti-inflammatory, antipruritic, anti-allergic, anti-exudative effects.

The mechanism of anti-inflammatory action is not fully understood. Fluocinolone acetonide inhibits the synthesis of prostaglandins and leukotrienes by inhibition of phospholipase A2 activity and reduces the release of arachidonic acid from phospholipids of the cell membrane. It prevents local allergic reactions in the skin. Antiexudative effect is caused by the vasoconstrictor action.

Pharmacokinetics

Easy penetration into the skin through the stratum corneum. Does not undergo biotransformation in the skin and cumulates in the stratum corneum. Fluociolone acetonide is detectable in the skin even after 15 days of topical application.

When used topically, fluocinolone acetonide may be slightly absorbed into the systemic bloodstream and cause general effects. The absorbed part is biotransformed mainly in the liver and is excreted from the body as compounds with glucuronic acid and in small amounts in unbound form. It is excreted mainly with urine and slightly with bile.

Absorption of fluocinolone acetonide is more pronounced when it is applied to the face and affected areas of the skin, as well as when using occlusive dressings. In addition, absorption of the drug increases when it is used frequently and when applied to large areas of skin. Absorption of the drug in children is more pronounced than in adults.

Indications

Acute and severe uninfected, dry inflammatory skin diseases of various origins, accompanied by itching and hyperkeratosis, treatable with GCS:

seborrheic dermatitis;
contact eczema;
atopic dermatitis;
psoriasis (including psoriasis of the scalp);
erythematous lichen;
erythema multiforme;
lichen planus;
impetiginous eczema.

Pharmacological effect

Flucinar is a synthetic GCS for external use. It has anti-inflammatory, antipruritic, anti-allergic, anti-exudative effects.

The mechanism of anti-inflammatory action is not fully understood. Fluocinolone acetonide inhibits the synthesis of prostaglandins and leukotrienes by inhibiting the activity of phospholipase A2 and reduces the release of arachidonic acid from cell membrane phospholipids. Prevents the occurrence of local allergic reactions in the skin. The antiexudative effect is due to the vasoconstrictor effect.

Pharmacokinetics

Easily penetrates the skin through the stratum corneum. It does not undergo biotransformation in the skin and accumulates in the stratum corneum. Fluociolone acetonide is detectable in the skin even 15 days after its topical application.

When fluocinolone is used externally, acetonide can be absorbed to a small extent into the systemic circulation and cause general symptoms. The absorbed part is biotransformed mainly in the liver and excreted from the body in the form of compounds with glucuronic acid and in a small amount in an unbound form. Excreted mainly in urine and slightly in bile.

Absorption of fluocinolone acetonide is more pronounced when applied to the face and affected areas of the skin, as well as when using occlusive dressings. In addition, absorption of the drug increases with frequent use and when applied to large areas of the skin. Absorption of the drug in children is more pronounced than in adults.

Special instructions

Long-term use of Flucinar should be avoided. With prolonged use of GCS over large areas of the skin, the incidence of adverse reactions in the form of peripheral edema, arterial hypertension, hyperglycemia, and immunosuppressive effects increases.

If a secondary infection develops at the site of application of the drug Flucinar, antibacterial and antifungal therapy should be prescribed.

The drug should be used with extreme caution on the skin of the eyelids or in the eye area in patients with glaucoma and cataracts, due to a possible increase in the symptoms of the disease.

When applied to the skin of the face, the absorption of the drug increases and even after short-term use the possibility of side effects (telangiectasia, skin atrophy, perioral dermatitis) increases. Use the drug in this area with extreme caution.

Flucinar should be prescribed with caution to persons with existing atrophic skin changes, especially elderly patients.

Active ingredient

Fluocinolone acetonide

Composition

Active ingredient:

fluocinolone acetonide 0.25 mg;

Excipients:

propylene glycol;

citric acid;

lanolin anhydrous;

Vaseline white.

Contraindications

Hypersensitivity;
acne;
bacterial (including tuberculosis), fungal, viral and tumor diseases of the skin.

Side Effects

Atrophy of the skin and subcutaneous fat, lupus-like syndrome with a mild course, the appearance or exacerbation of symptoms of lichen planus, epithelialization disorders, delayed healing of wounds and ulcerative lesions, petechiae, steroid purpura, stretch marks, hirsutism, baldness in women, maculopapular skin rash.

Overdose

Symptoms: if the dosage regimen is not followed (long-term use of the drug over large areas of the skin), systemic side effects of the drug may develop, such as increased blood pressure, edema, and immunosuppressive effects.

Treatment: drug withdrawal.

Storage conditions

At a temperature not exceeding 25 °C. Do not freeze.

Shelf life

3 years.

Manufacturer

Pharmaceutical plant Elfa A.O., Poland